# Correction to: Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways

**Authors:** Yang Li, Zhichao Xi, Xiaoqiong Chen, Shuangfan Cai, Chen Liang, Zhen Wang, Yingyi Li, Hongsheng Tan, Yuanzhi Lao, Hongxi Xu

PMC · DOI: 10.1038/s41419-025-07495-2 · 2025-04-25

## Full-text entities

- **Genes:** MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714] {aka ASV, SRC1, THC6, c-SRC, p60-Src}
- **Diseases:** pancreatic cancer (MESH:D010190)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12032033/full.md

---
Source: https://tomesphere.com/paper/PMC12032033